10x Genomics (NASDAQ: TXG) reported Q2 EPS of $0.28, $0.65 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $172.9 million versus the consensus estimate of $139.4 million.

GUIDANCE:

10x Genomics sees Q3 2025 revenue of $140-144 million, versus the consensus of $144.5 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.